These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 19482372

  • 1. Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma.
    Veit-Haibach P, Schaefer NG, Steinert HC, Soyka JD, Seifert B, Stahel RA.
    Lung Cancer; 2010 Mar; 67(3):311-7. PubMed ID: 19482372
    [Abstract] [Full Text] [Related]

  • 2. Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): value of 18F-FDG-PET/CT.
    Schaefer NG, Veit-Haibach P, Soyka JD, Steinert HC, Stahel RA.
    Eur J Radiol; 2012 Jan; 81(1):e19-25. PubMed ID: 21129871
    [Abstract] [Full Text] [Related]

  • 3. Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
    Kanemura S, Kuribayashi K, Funaguchi N, Shibata E, Mikami K, Doi H, Kitajima K, Hasegawa S, Nakano T.
    Eur J Radiol; 2017 Jan; 86():92-98. PubMed ID: 28027772
    [Abstract] [Full Text] [Related]

  • 4. Prognostic and predictive role of [18 F]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy.
    Zucali PA, Lopci E, Ceresoli GL, Giordano L, Perrino M, Ciocia G, Gianoncelli L, Lorenzi E, Simonelli M, De Vincenzo F, Setti LR, Bonifacio C, Bonomi M, Bombardieri E, Chiti A, Santoro A.
    Cancer Med; 2017 Oct; 6(10):2287-2296. PubMed ID: 28941158
    [Abstract] [Full Text] [Related]

  • 5. Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma.
    Lopci E, Zucali PA, Ceresoli GL, Perrino M, Giordano L, Gianoncelli L, Lorenzi E, Gemelli M, Santoro A, Chiti A.
    Eur J Nucl Med Mol Imaging; 2015 Apr; 42(5):667-75. PubMed ID: 25403555
    [Abstract] [Full Text] [Related]

  • 6. Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
    Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk AW, Millward MJ.
    J Nucl Med; 2007 Sep; 48(9):1449-58. PubMed ID: 17704250
    [Abstract] [Full Text] [Related]

  • 7. Feasibility and performance of an adaptive contrast-oriented FDG PET/CT quantification technique for global disease assessment of malignant pleural mesothelioma and a brief review of the literature.
    Marin-Oyaga VA, Salavati A, Houshmand S, Pasha AK, Gharavi M, Saboury B, Basu S, Torigian DA, Alavi A.
    Hell J Nucl Med; 2015 Sep; 18(1):11-8. PubMed ID: 25679073
    [Abstract] [Full Text] [Related]

  • 8. Clinical implications of 18F-fluorodeoxyglucose positron emission tomography/computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma.
    Abe Y, Tamura K, Sakata I, Ishida J, Ozeki Y, Tamura A, Uematsu K, Sakai H, Goya T, Kanazawa M, Machida K.
    Oncol Rep; 2012 Feb; 27(2):333-8. PubMed ID: 22024889
    [Abstract] [Full Text] [Related]

  • 9. Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose.
    Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, Salamina S, Incarbone M, Alloisio M, Santoro A.
    J Clin Oncol; 2006 Oct 01; 24(28):4587-93. PubMed ID: 17008700
    [Abstract] [Full Text] [Related]

  • 10. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma.
    Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, Kijima T, Hasegawa S, Kaida H, Yamakado K.
    Oncotarget; 2024 Jun 20; 15():408-417. PubMed ID: 38900646
    [Abstract] [Full Text] [Related]

  • 11. Does positron emission tomography offer prognostic information in malignant pleural mesothelioma?
    Sharif S, Zahid I, Routledge T, Scarci M.
    Interact Cardiovasc Thorac Surg; 2011 May 20; 12(5):806-11. PubMed ID: 21266493
    [Abstract] [Full Text] [Related]

  • 12. 18F-FDG PET/CT in therapy response and in predicting responders or non-responders in malignant pleural mesothelioma patients, by using semi-quantitative mRECIST and EORTC criteria.
    Niccoli Asabella A, Di Palo A, Altini C, Fanelli M, Ferrari C, Lavelli V, Ranieri G, Gadaleta CD, Rubini G.
    Hell J Nucl Med; 2018 May 20; 21(3):191-197. PubMed ID: 30411729
    [Abstract] [Full Text] [Related]

  • 13. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul 20; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 14. Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
    Abakay A, Komek H, Abakay O, Palanci Y, Ekici F, Tekbas G, Tanrikulu AC.
    Eur Rev Med Pharmacol Sci; 2013 May 20; 17(9):1233-41. PubMed ID: 23690193
    [Abstract] [Full Text] [Related]

  • 15. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J, Ramlau R, Santoro A, Schuette W, Chemaissani A, Hong S, Blatter J, Adachi S, Hanauske A, Manegold C.
    J Clin Oncol; 2008 Apr 01; 26(10):1698-704. PubMed ID: 18375898
    [Abstract] [Full Text] [Related]

  • 16. [Usefulness of 18F-FDG PET-CT in the presurgical assessment of malignant pleural mesothelioma treated with neoadjuvant chemotherapy].
    Orcajo Rincón J, Alonso Farto JC, Rotger Regi A, Hernández Pérez R, Hualde AM, Pérez Aradas V.
    Rev Esp Med Nucl; 2011 Apr 01; 30(5):307-10. PubMed ID: 21641092
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of metabolic response by positron emission tomography after neoadjuvant chemotherapy for resectable malignant pleural mesothelioma.
    Tsutani Y, Takuwa T, Miyata Y, Fukuoka K, Hasegawa S, Nakano T, Okada M.
    Ann Oncol; 2013 Apr 01; 24(4):1005-10. PubMed ID: 23136224
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA, Wozniak AJ, Belani CP, Keohan ML, Ross HJ, Polikoff JA, Mintzer DM, Ye Z, Monberg MJ, Obasaju CK, Pemetrexed expanded access program investigators.
    J Thorac Oncol; 2006 Jul 01; 1(6):506-12. PubMed ID: 17409909
    [Abstract] [Full Text] [Related]

  • 19. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review.
    Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG.
    Anticancer Res; 2013 Sep 01; 33(9):3553-61. PubMed ID: 24023280
    [Abstract] [Full Text] [Related]

  • 20. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program.
    Santoro A, O'Brien ME, Stahel RA, Nackaerts K, Baas P, Karthaus M, Eberhardt W, Paz-Ares L, Sundstrom S, Liu Y, Ripoche V, Blatter J, Visseren-Grul CM, Manegold C.
    J Thorac Oncol; 2008 Jul 01; 3(7):756-63. PubMed ID: 18594322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.